BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 29575055)

  • 1. MicroRNA-190b regulates lipid metabolism and insulin sensitivity by targeting IGF-1 and ADAMTS9 in non-alcoholic fatty liver disease.
    Xu M; Zheng XM; Jiang F; Qiu WQ
    J Cell Biochem; 2018 Jul; 119(7):5864-5874. PubMed ID: 29575055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
    Liu X; Chen S; Zhang L
    Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease.
    Fu D; Cui H; Zhang Y
    Cell Physiol Biochem; 2018; 45(6):2187-2198. PubMed ID: 29550812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-185 regulates expression of lipid metabolism genes and improves insulin sensitivity in mice with non-alcoholic fatty liver disease.
    Wang XC; Zhan XR; Li XY; Yu JJ; Liu XM
    World J Gastroenterol; 2014 Dec; 20(47):17914-23. PubMed ID: 25548489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of miR-181a impairs lipid metabolism by targeting PPARĪ± expression in nonalcoholic fatty liver disease.
    Huang R; Duan X; Liu X; Cao H; Wang Y; Fan J; Wang B
    Biochem Biophys Res Commun; 2019 Jan; 508(4):1252-1258. PubMed ID: 30558790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator.
    Zhuge B; Li G
    Biochem Biophys Res Commun; 2017 Dec; 494(3-4):687-692. PubMed ID: 29107687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
    Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARĪ³ axis in non-alcoholic fatty liver disease.
    Liu J; Tang T; Wang GD; Liu B
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31064820
    [No Abstract]   [Full Text] [Related]  

  • 9. miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR.
    Sun C; Huang F; Liu X; Xiao X; Yang M; Hu G; Liu H; Liao L
    Int J Mol Med; 2015 Mar; 35(3):847-53. PubMed ID: 25605429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR.
    Nie H; Song C; Wang D; Cui S; Ren T; Cao Z; Liu Q; Chen Z; Chen X; Zhou Y
    Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3087-3094. PubMed ID: 28951211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-regulation of microRNA-190b plays a role for decreased IGF-1 that induces insulin resistance in human hepatocellular carcinoma.
    Hung TM; Ho CM; Liu YC; Lee JL; Liao YR; Wu YM; Ho MC; Chen CH; Lai HS; Lee PH
    PLoS One; 2014; 9(2):e89446. PubMed ID: 24586785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance.
    Kim HY; Park SY; Lee MH; Rho JH; Oh YJ; Jung HU; Yoo SH; Jeong NY; Lee HJ; Suh S; Seo SY; Cheong J; Jeong JS; Yoo YH
    J Hepatol; 2015 Aug; 63(2):477-85. PubMed ID: 25646886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NFE2 Induces miR-423-5p to Promote Gluconeogenesis and Hyperglycemia by Repressing the Hepatic FAM3A-ATP-Akt Pathway.
    Yang W; Wang J; Chen Z; Chen J; Meng Y; Chen L; Chang Y; Geng B; Sun L; Dou L; Li J; Guan Y; Cui Q; Yang J
    Diabetes; 2017 Jul; 66(7):1819-1832. PubMed ID: 28411267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-188 promotes liver steatosis and insulin resistance via the autophagy pathway.
    Liu Y; Zhou X; Xiao Y; Li C; Huang Y; Guo Q; Su T; Fu L; Luo L
    J Endocrinol; 2020 Jun; 245(3):411-423. PubMed ID: 32252024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
    Long JK; Dai W; Zheng YW; Zhao SP
    Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1.
    Zhang M; Sun W; Zhou M; Tang Y
    Sci Rep; 2017 Nov; 7(1):14493. PubMed ID: 29101357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-26a-interleukin (IL)-6-IL-17 axis regulates the development of non-alcoholic fatty liver disease in a murine model.
    He Q; Li F; Li J; Li R; Zhan G; Li G; Du W; Tan H
    Clin Exp Immunol; 2017 Jan; 187(1):174-184. PubMed ID: 27377869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-205 ameliorates lipid accumulation in non-alcoholic fatty liver disease through targeting NEU1.
    Hu Y; Ye H; Shi LX
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):10072-10082. PubMed ID: 31799678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-376b-3p ameliorates nonalcoholic fatty liver disease by targeting FGFR1 and regulating lipid oxidation in hepatocytes.
    Wang XY; Lu LJ; Li YM; Xu CF
    Life Sci; 2022 Nov; 308():120925. PubMed ID: 36057399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of long non-coding RNA Gm10804 suppresses disorders of hepatic glucose and lipid metabolism in diabetes with non-alcoholic fatty liver disease.
    Li T; Huang X; Yue Z; Meng L; Hu Y
    Cell Biochem Funct; 2020 Oct; 38(7):839-846. PubMed ID: 32212193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.